nach oben

Wiener klinische Wochenschrift

Erschienen in:

01.04.2013 | letter to the editor

Agomelatine-induced hepatotoxicity

verfasst von: Matej Štuhec, PharmD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2013

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Vorheriger Artikel Acetazolamide induced severe hepatotoxicity

Nächster Artikel Erratum to: Thyroid hormone levels as a predictor of mortality in intensive care patients: a comparative prospective study

Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today. 2009;45:599–608.PubMedCrossRef

Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–20.PubMedCrossRef

Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–31.PubMedCrossRef

Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–55.PubMedCrossRef

Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40:718–24.PubMed

Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 3. Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase. Clin Chem Lab Med. 2002;40:631–4.PubMed

Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30:135–44.PubMedCrossRef

Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 2006;21 Suppl 1:S31–5.

De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry. 2012;2012:642752.PubMed

10.

Müller H, Seifert F, Maler JM, et al. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients. Singapore Med J. 2012;53:e228–30.

Titel: Agomelatine-induced hepatotoxicity
verfasst von: Matej Štuhec, PharmD
Publikationsdatum: 01.04.2013
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 7-8/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-013-0344-0

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7-8/2013

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis

Erratum to: Thyroid hormone levels as a predictor of mortality in intensive care patients: a comparative prospective study

Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)

Acetazolamide induced severe hepatotoxicity

Level of hypertension control: comparison of a rural and urban family practice centre in South Croatia

Jahreshauptversammlung 2013